A panel of MYCN-amplified neuroblastoma organoids was employed to run a high-throughput screen, selecting the inhibitor of kinesin spindle protein, ARRY-520, as an agent to cause reduced organoid viability [64]. Here, MYCN is linked to neuroblastoma.